{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:39:06Z","timestamp":1791085146774,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>Adalimumab (ADA) has been shown to be an effective treatment for Beh\u00e7et\u2019s disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled patients diagnosed with BD-related uveitis and treated with ADA between January 2009 and December 2016. Cumulative survival rates were studied using the Kaplan-Meier plot, while the log-rank (Mantel-Cox) test was used to compare survival curves. Statistical analysis was performed to identify differences according to the response to ADA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>54 consecutive patients (82 eyes) were eligible for analysis. The drug retention rate at 12- and 48-month follow-up was 76.9% and 63.5%, respectively. No statistically significant differences were identified according to the use of concomitant DMARDs (p=0.27) and to the different lines of ADA treatment (p=0.37). No significant differences were found between patients continuing and discontinuing ADA in terms of age (p=0.24), age at BD onset (p=0.81), age at uveitis onset (p=0.56), overall BD duration (p=0.055), uveitis duration (p=0.46), human leucocyte antigen-B51 positivity (p=0.51), and gender (p=0.47).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ADA retention rate in BD-related uveitis is excellent and is not affected by the concomitant use of DMARDs or by the different lines of biological therapy. Negative prognostic factors for BD uveitis do not impact ADA efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310733","type":"journal-article","created":{"date-parts":[[2017,8,27]],"date-time":"2017-08-27T00:10:20Z","timestamp":1503792620000},"page":"637-641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: a four-year follow-up study"],"prefix":"10.1136","volume":"102","author":[{"given":"Claudia","family":"Fabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Vannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bacherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,26]]},"reference":[{"key":"2020050713011099000_102.5.637.1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11739-013-1036-5","article-title":"Beh\u00e7et\u2019s syndrome pathophysiology and potential therapeutic targets","volume":"9","author":"Emmi","year":"2014","journal-title":"Intern Emerg Med"},{"key":"2020050713011099000_102.5.637.2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.723112"},{"key":"2020050713011099000_102.5.637.3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","article-title":"Review for diagnostics of the year: multimodal imaging in Beh\u00e7et uveitis","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"2020050713011099000_102.5.637.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.11.019"},{"key":"2020050713011099000_102.5.637.5","first-page":"S175","article-title":"A systematic literature review on the treatment of major organ involvement of Beh\u00e7et\u2019s syndrome informing the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"34","author":"Ozguler","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2020050713011099000_102.5.637.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"2020050713011099000_102.5.637.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"2020050713011099000_102.5.637.8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"2020050713011099000_102.5.637.9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2020050713011099000_102.5.637.10","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2010.483314"},{"key":"2020050713011099000_102.5.637.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes130"},{"issue":"4 Suppl 84","key":"2020050713011099000_102.5.637.12","first-page":"S58","article-title":"Adalimumab for treatment of severe Beh\u00e7et\u2019s uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2020050713011099000_102.5.637.13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/319215"},{"key":"2020050713011099000_102.5.637.14","first-page":"1078","article-title":"International study group for Beh\u00e7et\u2019s disease","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","journal-title":"Lancet"},{"key":"2020050713011099000_102.5.637.15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10067-013-2411-3","article-title":"Validation of the revised International Criteria for Behcet\u2019s Disease (ICBD) in Iran","volume":"34","author":"Davatchi","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2020050713011099000_102.5.637.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0484-y"},{"key":"2020050713011099000_102.5.637.17","doi-asserted-by":"crossref","unstructured":"Vitale A , Emmi G , Lopalco G , et al . Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease. Clin Rheumatol 2017. Epub ahead of print.doi:10.1007\/s10067-017-3627-4","DOI":"10.1007\/s10067-017-3627-4"},{"key":"2020050713011099000_102.5.637.18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","article-title":"Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2020050713011099000_102.5.637.19","doi-asserted-by":"crossref","unstructured":"Cantarini L , Talarico R , Generali E , et al . Safety profile of biologic agents for Beh\u00e7et\u2019s disease in a multicenter observational cohort study. Int J Rheum Dis 2015. Epub ahead of print.","DOI":"10.1111\/1756-185X.12732"},{"key":"2020050713011099000_102.5.637.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)31022-6"},{"key":"2020050713011099000_102.5.637.21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.humimm.2013.06.036","article-title":"Genetic and non-genetic factors affecting the visual outcome of ocular Behcet\u2019s disease","volume":"74","author":"Kang","year":"2013","journal-title":"Hum Immunol"},{"key":"2020050713011099000_102.5.637.22","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200301000-00006"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:45Z","timestamp":1601110545000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,26]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310733"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310733","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,26]]}}}